News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VC Firm Raises $310 Million Fund to Inject Into Life Science and Healthcare Companies



7/29/2013 7:45:16 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Telegraph Hill Partners Raises $310M Fund for New Investments in Life Science and Healthcare Companies

SAN FRANCISCO, CA--(Marketwired - July 29, 2013) - Telegraph Hill Partners (THP), a leading venture capital and growth equity firm dedicated exclusively to life science and healthcare investing, has had its final closing on a new $310 million fund and plans to use it to help finance innovative enterprises on the verge of expansion. The fund, THP III, is Telegraph Hill Partners' largest since the firm was formed in 2001.

"Capital commitments exceeded our target and represent a new record for THP," stated Matt Mackowski, Chairman of THP. "We are delighted by the participation of our existing limited partners and are gratified to have added several new investors to the fund. We also thank the leaders of our portfolio companies because their exceptional performance was a key component in enabling our firm to reach this significant milestone."

Consistent with its previous funds, THP III will invest in companies with advanced technologies that have already demonstrated organic revenue growth and a superior business model. Areas of focus include life science tools, reagents, specialty chemistries, medical technology, medical devices, healthcare IT, healthcare services, agriculture and animal health.

THP utilizes an extensive range of investment structures to effectively address the capital needs of each company. These structures range from venture capital to growth equity to buyouts and secondary acquisitions. With the new fund, Telegraph Hill Partners expects to invest in 10-12 innovative, high-growth companies across the United States. THP's previous investments include Althea Technologies (acquired by Ajinomoto Co.), Ambion, (acquired by Applied Biosystems Group), Dharmacon (acquired by ThermoFisher), NEXUS Biosystems (acquired by Brooks Automation), LDR (based in Austin, TX) and Vidacare (based in San Antonio, TX).

Ronald Seubert, President and Chief Executive Officer of RareCyte, worked with Telegraph Hill Partners when he held the same positions at Applied Precision, a THP portfolio company that was acquired by GE Healthcare. "THP was an active partner with us. They provided strategic guidance and practical advice in many areas that helped us grow our business, achieve profitability and establish our company as a leading life sciences instruments business."

About Telegraph Hill Partners

Telegraph Hill Partners, founded in 2001 and based in San Francisco, CA, invests in commercial stage life science, medical technology and healthcare companies. For more information please see www.telegraphhillpartners.com.


For further information:

Alan Zachary
HDM
312/506-5220
mobile: 708/707-6834
azachary@harrisdmckinney.com



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES